The putative serine protease PRSS16 is abundantly expressed in the thymic cortex and the gene is encoded within the HLA I complex. Although its function is not yet defined, the very restricted expression points to a role in T-cell development in the thymus. In this study, we show that the PRSS16 mRNA is alternatively spliced to generate at least five transcripts. Apart from the full-length sequence, we found two other isoforms with all putative active site residues of the serine protease, suggesting that those variants may also be functional. Semi-quantitative analysis of the splice variants in different tissue samples revealed a strong correlation between the specific formation of alternatively spliced PRSS16 transcripts and the age and thymus pathology status of the donor. Newborn thymi express mostly the PRSS16-4 and -5 isoforms and lack the PRSS16-1 transcript, which appears around 2 years of age and stays until adulthood. Incidentally, thymi from myasthenia gravis (MG) patients with thymoma showed a marked decrease in the expression of the full-length PRSS16-1 and increased expression of the smaller isoforms. The data suggest a potential role of the PRSS16 isoforms in the postnatal morphogenesis of the thymus and in the thymus pathology related to MG.
Introduction
PRSS16, also known as TSSP for thymus-specific serine protease, is highly expressed in the thymic cortex both in humans 1 and mice. 2 The function of PRSS16 is not yet elucidated, but its restricted distribution to the thymus gland and the fact that the embryonic expression starts in mice at the same time point that the thymic anlage is populated by T-cell precursors 3 support a role for this protease in the maturation or migration of thymocytes. In humans, the PRSS16 gene is located in the far distal class I region, 2.7 megabases telomeric to HLA-A, suggesting that it may be involved in events related to antigen presentation in the thymic cortex. 1 Additionally, Prss16 has been recently described as a potential susceptibility gene for autoimmunity in nonobese diabetic NOD and New Zealand Black mice, 3 two strains characterized by the spontaneous development of insulin-dependent diabetes mellitus.
Myasthenia gravis (MG) is a classical example of an antibody-mediated autoimmune disease characterized by progressive disappearance of the nicotinic acetylcholine receptor (AChR) at the neuromuscular junction and thymic abnormalities. An abnormal thymic architecture is a frequent finding in MG, and thymectomy is beneficial in many occasions. At least 10% of all myasthenic patients show thymoma, whereas thymitis is found in most of the early-onset cases. 4, 5 This thymitis or thymic lymphofollicular hyperplasia (TFH) is characterized by the presence of germinal centers within the thymic medulla, 6, 7 which support expansion and affinity maturation of B-cell clones and facilitate the production and export of AChR-specific antibodies. 8 AChR-specific T cells are found in the myasthenic thymus, 9 and T-cell lines could be established from thymi from myasthenia patients, 10 suggesting that autoantigen-specific T cells mature in the pathologically transformed thymus and influence the humoral immune response in the periphery. 11 To test whether PRSS16 is altered in the thymus of MG patients, we investigated the expression of this protease in thymi from healthy controls and in thymic samples from patients with MG. We found that PRSS16 is alternatively spliced in the human thymus. Qualitative and quantitative differences in the expression of the splice variants could be detected depending on the age of the donor and the thymic pathology, suggesting a role of PRSS16 in the postnatal morphogenesis of the thymus and in the thymus pathology related to MG.
Results

PRSS16 is alternatively spliced in the human thymus
During the cloning of the PRSS16 cDNA, multiple PCRs that amplified overlapping areas spanning the complete coding sequence were performed. The nested primer pair PRSS16-6F/PRSS16-536R amplified specifically the 5 0 -end of the cDNA and resulted in one single PCR product with the expected size of 531 bp (data not shown). A second amplification with the nested primer pair PRSS16-882F/PRSS16-1702R yielded a single product of 831 bp corresponding to the expected unspliced transcript for the PRSS16 3 0 -end. The amplification of the middle region of the PRSS16 gene was carried out with the nested primer pair PRSS16-339F and PRSS16-1169R, spanning from exon 3 to exon 10. Surprisingly, we obtained five different PCR products with amplicon lengths of 831, 542, 492, 414 and 290 bp, which where individually isolated from the gel, cloned, sequenced and given the names PRSS16-1-5, respectively ( Figure 1 ).
Sequence analysis revealed that the 831 band represents the full-length cDNA (PRSS16-1) as resported by Bowlus et al (GenBank Accesion Number AF052514), 1 whereas the shorter PCR products are derived from alternatively spliced PRSS16 transcripts ( Figure 2 ). The 542 bp amplicon (PRSS16-2, GenBank AY305025) was identical to the full-length cDNA, with the exception that exons 8 and 9 were shortened: exon 8 exhibited a truncation of 214 bp at the 3 0 -end and exon 9 a truncation of 74 bp at the 5 0 -end, resulting in the formation of a stop codon exactly at the border of both exon fragments. The 492 bp PCR product (PRSS16-3, GenBank AY305022) represents a sequence in which exon 6 is spliced directly to exon 9. The predicted amino-acid sequence of this transcript contains all active site residues of the fulllength thymus-specific serine protease, as deduced from alignment searches showing a sequence homology with the serine protease prolylcarboxypeptidase (PCP). 1 Just like in the full-length transcript of PRSS16, a stop codon was present at positions 70-72 bp of exon 12. The 414 bp band (PRSS16-4, GenBank AY305024) results from skipping exons 6-8. Similar to the PRSS16-3 amplicon, the transcript corresponding to the 414-bp PCR product is predicted to keep all active site residues. Finally, the sequence analysis of the shortest fragment of 290 bp (PRSS16-5, GenBank AY305023) revealed that exons 5-8 were skipped, resulting in a frame-shift and the formation of a stop codon at positions 32-34 of exon 9 ( Figure 2 ). In summary, five isoforms for the PRSS16 gene were found in the thymus of normal donors, and three of them maintained the putative active site residues of the protease (Table 1 ). Figure 1 The human PRSS16 gene is alternatively spliced. Four transcripts of the PRSS16 gene in addition to the full-length product were identified after nested PCR amplification of cDNA from human normal thymus. The PRSS16 splice variants are differentially expressed in relation to the age of the thymus donor In order to investigate whether the splice variants were present in all individuals, we performed the nested PCR using the primer pairs PRSS16-339F and PRSS16-1169R, with a panel of 14 cDNA from thymi from healthy donors, from newborns until 48-year-old adults (Figure 3a) . A pattern of RNA expression emerged, in which postnatal thymi showed a variable expression profile, where the longest form PRSS16-1 was prominent in all the samples after 2 years of age, while in the younger donors it was prominent in two out of seven donors. The variant PRSS16-4 was expressed at very different levels, and PRSS16-5 was weakly expressed in all specimens. The relative abundance of these two smaller isoforms was variable in the different samples. Thymi from donors after 2 years of age showed very consistently all three major bands: the long form PRSS16-1, together with the shorter variants PRSS16-4 and PRSS16-5. The isoforms PRSS16-2 and -3 were present only occasionally in the younger (less than 2 years) thymi, and absent in all thymi from donors over two years of age. Quantitative analysis of the isoforms was performed by real-time PCR using minor groove binding (MGB) probes for the PRSS16-1, -4, and -5 variants (Figure 3b ). The results correlate with the agarose gel analysis, showing that, in general, all variants are more prominent in thymi from children after 2 years of age 
The numbers identify the position of the first nucleotide of the primer-annealing sites in PRSS16 (GenBank accesion number AF052514). 1 The first primer pair PRSS16-6F/PRSS16-1702R amplifies from exon 1 to exon 12 and was used for the first round of amplification of the nested PCR. PRSS16 alternatively spliced in human thymus C Luther et al (P ¼ 0.007 for PRSS16-1, P ¼ 0.0404 for PRSS16-4 and P ¼ 0.006 for PRSS16-5). Due to the difficulty in finding specific regions for primers and probes for the variants PRSS16-2 and -3, these were not analyzed by real-time PCR. Altogether, these data suggest that the alternative spliced forms of PRSS16 may have a functional role in the development of the thymus after birth.
Differential expression of PRSS16 splice variants in the thymus from MG patients In all, 80% of the patients with MG show some degree of thymic pathology, and they mostly undergo thymic surgery, giving us the chance to study this material. We have separated the MG samples in two subgroups ( Table 2) : five patients with MG-associated TFH (MG1-MG5) and seven patients with MG-associated thymoma (MGT6-MGT12, typically cortical type) were analyzed and compared to normal thymi over 2 years of age. We performed RT-PCR as described above to identify any preferred pattern of splice variants within the different cDNA populations (Figure 4 ). In patients with TFH, no significant differences in the expression of the PRSS16-1, -4 and -5 splice variants were detected in comparison to control thymi. Of note, the variants PRSS16-2 and -3, which were only analyzed by conventional PCR, showed their presence in four of the five thymi with TFH (data not shown), but were not clearly detected in any of the normal thymi over 2 years of age (Figure 3a) . In the group of MG-associated thymoma, a significant decrease of PRSS16-1 was observed (Figure 4) , reminiscent of the samples of less than 2 years of age. On the other side, a tendency to higher levels of the smallest variant PRSS16-5 was observed, but the differences were nonsignificant. We had the chance to analyze four thymoma samples from non-MG patients (one mixed thymoma and three medullary epithelial cell thymoma), and found no decrease in the expression of PRSS16-1, absence of the isoforms PRSS16-2 and -3, and no major differences in the expression of PRSS16-4 and -5, a pattern very similar to normal thymi from donors over 2 years of age (data not shown). In summary, the heterogeneous thymic pathology of the myasthenic Figure 4 Patterns of expression of the PRSS16 transcripts in the thymi from patients with MG. Real-time PCR analysis of the PRSS16-1, -4 and -5 splice variants. Six samples from healthy donors (HD), five samples from MG-associated thymic follicular hyperplasia patients and seven samples from patients with MG-associated thymoma were analyzed. 18S rRNA was taken for standardization of the cDNA amounts and the thymus corresponding to the youngest donor was set as the basal level ( ¼ 1) for relative quantification. One outlier (Grubb's test) was detected for PRSS16-4 in the group TM (not depicted).
PRSS16 alternatively spliced in human thymus
C Luther et al patients is reflected in the differential splicing of the PRSS16 gene.
Discussion
The molecular processes that contribute to the antigen processing and presentation at the thymic level are still poorly understood, especially how the antigenic determinants that shape the T-cell repertoire are selected. Cathepsin B is a major cysteine protease involved in protein degradation for antigen presentation in peripheral antigen-presenting cells, 12 and recent work has shown how a single protease present in the thymus, asparagine endopeptidase, can create or destroy protein epitopes from myelin basic protein, which are relevant for autoimmune disease. 13 What is not clear yet is how then these epitopes are made available in the periphery to elicit autoreactivity, 14 but of course a differential display of protease activity in both compartments or in health and disease is an attractive idea. While many of the proteases are ubiquitously expressed throughout the body, a few of them are tissue-specific, such as the cysteine proteases cathepsin S in the peripheral antigenpresenting cells 15 and cathepsin V in the human thymic cortex. 16, 17 Both of them have been implicated in the last step of the degradation of invariant chain, a key process in MHC class II antigen presentation, 18 and play a major role in the control of the immune response and autoimmunity. 19 Indeed, the use of cathepsin S inhibitors prevents disease in a murine model for Sjö gren syndrome, 20 and cathepsin V is upregulated in the thymus from MG patients.
17
PRSS16 is a recently described serine protease that is also expressed exclusively in the thymic cortex, 1 exactly where the events leading to positive selection take place. 21 Moreover, the initiation of expression of Prss16 in the mouse has been mapped between days 11 and 15 of gestation, 3 a time point compatible with a role in T-cell development. We have identified four splice variants of the PRSS16 in addition to the full-length form, and analyzed their relative expression in human thymi. In healthy donors, we found that the full-length form was mostly absent in the newborn donors, appeared between 2 and 3 years of age when changes characteristic of thymic involution begin, and remained present in adulthood. The reduction in the cell number of the thymic microenvironment over the years is a genetically pre-programmed and well-controlled physiological process, 22 and is reflected in the slow-down of T-cell export observed in normal individuals already in the first years of life. 23 Thus, it can be speculated that PRSS16 has a function in thymic development. The only splice variant of PRSS16 that was constitutively expressed in nearly all samples, independently of the age of the donor, is PRSS16-4. Since PRSS16-4 is one of the three splice variants that encodes for a potentially proteolytic active enzyme, we speculate that there might be some catalytic redundancy between PRSS16-1 and -4. In most of the samples, PRSS16-1 and -4 are co-expressed with the shortest splice variant PRSS16-5. Whether this is due to the sequence-specific action of the spliceosome and results in a nonfunctional side product (PRSS16-5) remains unclear. This isoform could also represent an endogenous inhibitor, since it does not contain one of the three amino acids that constitute the putative active center, but contains the initial exons where the natural inhibitory proform is encoded.
Thymic pathology is found in nearly 90% of the MG patients, TFH being the most common finding in patients who develop MG before 40 years of age. 24 The presence of germinal centers and maturation of B cells in the thymus support the idea of presentation of autoantigens and development of autoreactive cells that escape the mechanisms of negative selection, although it is currently unknown whether the pathology originates in the thymus or if the thymus is filled with autoreactive T cells that have re-entered the thymus after being activated in the periphery. 10 As a paraneoplastic syndrome in thymomas, about 40% of patients have MG and are positive for anti-AChR autoantibodies, and, vice versa, thymic tumors are found in about 10% of the MG patients, usually between 40 and 60 years of age. Thymic tumors associated with MG are predominantly thymomas of the cortical, mixed or medullary subtype, or welldifferentiated thymic carcinoma, and it is suspected that the etiology of the MG-associated thymoma is different from that of MG-associated TFH. 25, 26 These tumors are also characterized by frequent genetic aberrations. 27 The expression pattern of PRSS16 splice variants in non-MGassociated thymoma is comparable to the phenotype of healthy adult thymi, where the PRSS16-1 form is dominant. By contrast, in the cases with MG-associated thymoma, PRSS16-1 form is markedly reduced, the PRSS16-5 is expressed at higher levels and the minor forms PRSS16-2 and -3 become apparent. One plausible explanation is that, in those patients, the program of the thymus is set up to a higher output of T cells, similar to the newborn thymus. Even if there is a continuous thymic output of T cells throughout the human lifespan, 28 the morphological changes of the thymus before and during adulthood cause an age-dependent decline in recent thymic emigrants. 29 This may reflect that the different thymic stages fit the different requirements, where newborns need to establish very fast an adaptive immune response against a broad repertoire of unknown pathogens. Then, the 'infant' expression pattern of the PRSS16 splice variants observed in young individuals and in adult MG patients with thymoma might contribute to the previously observed increase in recent thymic emigrant cells in patients with MG-associated thymoma. 30, 31 Interestingly, Prss16 in mice is expressed in the cortical thymic epithelium 32 and reaches its highest level in 16-day-old embryos. 3 Furthermore, while in WT mice Prss16 is weakly expressed, in T-cell deficient mice such as CD3e-and RAG1-knockout mice, the expression of this protease is dramatically increased. 32 Thus, PRSS16 may contribute to the development of the embryogenic thymus and to regulatory mechanisms during thymopoiesis. Nearly two-thirds of early-onset patients with TFH are HLA-B8 and DR3 positive, while B7 and DR2 are frequent alleles found in patients developing myasthenia symptoms at later ages (reviewed in Vincent et al 24 ). The strong effects of the MHC region on disease susceptibility suggest a role of this gene cluster in the etiopathogenesis of autoimmune disease. The PRSS16 gene lies within the HLA class I region and, indeed, Lie et al 33, 34 have shown that the region encoding the human PRSS16 gene is in great disequilibrium linkage in patients with insulin-dependent diabetes mellitus and PRSS16 alternatively spliced in human thymus C Luther et al celiac disease independently of the HLA-DR and -DQ genes. In addition, lower levels of PRSS16 were detected in the thymi of the spontaneously autoimmune mouse strains NZB and NOD when compared to normal B6 mice. 3 We are currently checking any associations between HLA alleles and PRSS16 polymorphisms in patients with MG.
Although some alternative splicing events appear to be constitutive, this mechanism is also widely involved in the regulation of tissue and developmental stagespecific gene expression. 35 It is possible that the splicing of PRSS16 plays a role in the normal organogenesis of the thymus, and it is then dysregulated in a disease like MG, very often linked to thymic pathology.
Materials and methods
Tissue specimens
Normal human thymi were obtained following the Institutional Review Board guidelines from patients undergoing corrective cardiac surgery in our hospital. Thymi from MG patients were obtained during therapeutic thymectomy (Table 2 ). Representative blocks of each tissue sample were frozen and stored at À701C until use.
Cloning of the human PRSS16
Tissue samples were lysed in Trizol (Life Tech., Grand Island, NY, USA), and the RNA extracted following the manufacturer's protocol. First-strand cDNA was prepared from total RNA by reverse transcription using the Superscript s RNase H À Reverse Transcriptase (Life Tech., Grand Island, NY, USA) and random hexamers (Pharmacia, Uppsala, Sweden). The cDNA was amplified by a first (booster) PCR reaction using a primer complementary to the 5 0 -end (PRSS16-6F) and one from the noncoding region, near the 3 0 -end (PRSS16-1702R) at a final concentration of 0.06 mM. This first amplification step was performed using HotStar-Taq polymerase (QIAGEN, Hilben, Germany). The following conditions were used for the first PCR: 951C for 15 min, for one cycle; 951C for 30 s, 601C for 1 min, 721C for 1 min, for 16 cycles; and a final extension at 721C for 10 min. The diluted first-round PCR products were used as a template (final dilution 1 : 25) for a nested PCR with the primer pairs PRSS16-6F/PRSS16-536R, PRSS16-339F/ PRSS16-1169R and PRSS16-882F/PRSS16-1702R ( Table 2 ). The following conditions were used for the nested PCR: 941C for 15 min, 30 cycles involving each 951C for 15 s, 601C for 1 min and 721C for 1 min, and a final extension step at 721C for 10 min. The resulting PCR product was resolved by electrophoresis in a 1.2% agarose gel. Each of the different-sized amplicons was excised from the gel and the DNA was immediately extracted using the QIAquick Gel Extraction kit (QIA-GEN, Hilben, Germany).
The extracted PCR products were directly cloned into the pCR s 2.1 TOPO vector using the TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Positive samples were sequenced and the resulting nucleotide sequences were aligned to PRSS16 (accession number AF052514 1 ).
Analysis of PRSS16 splice variant expression
For semi-quantitative screening of thymic samples from healthy donors and from patients, the same nested PCR (using the internal primer pair PRSS16-339F/PRSS16-1169R) was performed as described above. The resulting PCR products were analyzed by agarose gel electrophoresis.
Real-time quantitative PCR analysis of PRSS16
The template cDNA was first amplified with a booster PCR using the primer pairs PRSS16-6F, PRSS16-1702R, HotStar-Taq polymerase (QIAGEN, Hilben, Germany) and the following conditions: 951C for 15 min, 20 cycles of 951C for 30 s, 601C for 1 min, 721C for 1 min and a final extension of 10 min. The products of the booster PCR (1 ml at 1 : 20 dilution) were amplified using specific primers, a MGB probe system 36 and the Taqman Universal PCR Master Mix in the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Darmstadt, Germany). During amplification of the specific target, the probe is degraded, leading to the physical separation of the 3 0 nonfluorescent quencher and the 5 0 FAM-labelled reporter dye, and resulting in a proportional increase of fluorescence. Primers and probes (sequences listed in Table 1 ) were designed with the help of the 'PrimerExpresst' software (Applied Biosystems). The primers were set to result in amplicons of 50 bp of length and the probes to detect each isoform specifically by spanning the exon-exon boundaries. The primer/probe combinations were first tested in positive control plasmids, each containing one of the isoforms, to check the efficiency of the PCR and specificity of the system. As an endogenous control and for the normalization of the starting amounts of material, the 18S rRNA gene was amplified using aspecific primers (Table 1 ) and the Sybrgreen PCR Master Mix (Applied Biosystems).
Statistical analysis
Unpaired t-test was used to compare the expression of the individual PRSS16 isoforms within the different groups of samples. The P-values were considered statistically significant if Po0.05. The Grubb's test was used to detect possible outliers, which were found in two cases and excluded from the statistical analysis.
